Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancer

2022 ◽  
Vol 164 (1) ◽  
pp. 3-4
Author(s):  
Nancy Nguyen ◽  
Rebecca Brooks ◽  
Gary Leiserowitz ◽  
Jeremy Chien
Keyword(s):  
Ovarian Cancer ◽  
Erk Pathway ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Mek Inhibitors

scholarly journals Sodium MRI with 3D-cones as a measure of tumour cellularity in high grade serous ovarian cancer

2019 ◽  
Vol 6 ◽  
pp. 156-162 ◽  
Author(s):  
Surrin S. Deen ◽  
Frank Riemer ◽  
Mary A. McLean ◽  
Andrew B. Gill ◽  
Joshua D. Kaggie ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Sodium Mri ◽  
Tumour Cellularity

Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients

2021 ◽  
Author(s):  
Anna P. Sokolenko ◽  
Tatiana V. Gorodnova ◽  
Ilya V. Bizin ◽  
Ekaterina Sh. Kuligina ◽  
Khristina B. Kotiv ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Therapy ◽  
Cancer Patients ◽  
High Grade ◽  
Serous Ovarian Cancer

scholarly journals Precision radiogenomics: fusion biopsies to target tumour habitats in vivo

2021 ◽  
Author(s):  
Mireia Crispin-Ortuzar ◽  
Evis Sala
Keyword(s):  
Ovarian Cancer ◽  
Ct Scans ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
High Degree ◽  
Degree Of Heterogeneity

SummaryHigh-grade serous ovarian cancer lesions display a high degree of heterogeneity on CT scans. We have recently shown that regions with distinct imaging profiles can be accurately biopsied in vivo using a technique based on the fusion of CT and ultrasound scans.

Sign in / Sign up

Export Citation Format

Share Document